Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
14 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Sealantium Medical Belgium from Diepenbeek, company number BE1012599727, closed financial year 2025 with a result of € -7,486 after tax. For that financial year Sealantium Medical Belgium recorded a gross margin of € -7,311 and equity of € 26,210. Compared with financial year 2024, the result moved from € -16,305 to € -7,486. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 11, 2026.
€ 26,210
▼ 22% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -7,486
▲ 54 % less loss than in 2024
Profit after tax over the fiscal year.
€ 4,988
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -23,790.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 670
Supplier invoices still open on the last day of the fiscal year.
€ 1,875
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € -16,305 | € -7,311 | ▲ € 8,994 |
| Profit after taxes | € -16,305 | € -7,486 | ▲ € 8,819 |
| Equity | € 33,695 | € 26,210 | ▼ 22% |
| Total debts | € 19,633 | € 29,823 | ▲ 52% |
| Cash | - | € 4,988 | |
| Retained profit | € -16,305 | € -23,790 | ▼ € 7,486 |
| Balance sheet total | € 53,328 | € 56,033 | ▲ 5% |
Key figures of Sealantium Medical Belgium, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Sealantium Medical Belgium?
What happened at Sealantium Medical Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 7,486. Source: NBB ↗
- Bart Van Acker became a director. NBB
- Christopher Charles Lamb became a director. NBB
- New establishment in Diepenbeek. KBO
- Sealantium Medical Ltd. became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 16,305 loss in 2024 to € 7,486 loss in 2025.
Management
Behind Sealantium Medical Belgium are Sealantium Medical Ltd., Bart Van Acker and Christopher Charles Lamb. The shares are held by Sealantium Medical Ltd. (100%).
Directors
According to the 2025 annual accounts
Director · represented by Orgad Laub
since 2024
Bart Van Acker
Director
since 2025
Christopher Charles Lamb
Director
since 2025
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Agoralaan Abis
3590 Diepenbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 14 companies are registered at this address.
All companies at this address →Clinitude
€ 419,430 gross margin · 2025
FOx Biosystems
€ -763,895 gross margin · 2023
Highstar Engineering
€ -52,153 gross margin · 2025
IDEA FAMILY
€ -1,811 gross margin · 2026
BIOKEY
€ -16,079 gross margin · 2026
+9 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1012.599.727
- VAT number
- BE 1012.599.727
- Registered office
- Agoralaan Abis, 3590 Diepenbeek
- Names & denominations
- Sealantium Medical Belgium
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 20 August 2024
- Peppol
- Active · Active since 21 Oct 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied